ZA200709780B - Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues - Google Patents
Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissuesInfo
- Publication number
- ZA200709780B ZA200709780B ZA200709780A ZA200709780A ZA200709780B ZA 200709780 B ZA200709780 B ZA 200709780B ZA 200709780 A ZA200709780 A ZA 200709780A ZA 200709780 A ZA200709780 A ZA 200709780A ZA 200709780 B ZA200709780 B ZA 200709780B
- Authority
- ZA
- South Africa
- Prior art keywords
- egfr
- copy number
- tumor tissues
- antibody therapy
- therapy based
- Prior art date
Links
- 101150039808 Egfr gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 238000009175 antibody therapy Methods 0.000 title 1
- 108700021358 erbB-1 Genes Proteins 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05008156 | 2005-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200709780B true ZA200709780B (en) | 2008-11-26 |
Family
ID=36645327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200709780A ZA200709780B (en) | 2005-04-14 | 2007-11-13 | Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues |
Country Status (12)
Country | Link |
---|---|
US (1) | US20090269344A1 (zh) |
EP (1) | EP1869208A1 (zh) |
JP (1) | JP2008535508A (zh) |
KR (1) | KR20080003422A (zh) |
CN (1) | CN101155932A (zh) |
AU (1) | AU2006233675A1 (zh) |
BR (1) | BRPI0610440A2 (zh) |
CA (1) | CA2604300A1 (zh) |
MX (1) | MX2007012570A (zh) |
RU (1) | RU2007141067A (zh) |
WO (1) | WO2006108627A1 (zh) |
ZA (1) | ZA200709780B (zh) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006107854A2 (en) * | 2005-04-01 | 2006-10-12 | Amgen Inc. | Epidermal growth factor receptor gene copy number |
US7908091B2 (en) | 2006-03-17 | 2011-03-15 | Prometheus Laboratories Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
CA2676049C (en) | 2007-03-01 | 2018-04-10 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
CA2680326A1 (en) | 2007-03-13 | 2008-09-18 | Amgen Inc. | K-ras mutations and anti-egfr antibody therapy |
WO2008112274A2 (en) * | 2007-03-13 | 2008-09-18 | Amgen Inc. | K-ras and b-raf mutations and anti-egfr antibody therapy |
RU2540146C2 (ru) | 2008-08-29 | 2015-02-10 | Симфоген А/С | Композиции рекомбинантных антител против рецептора эпидермального фактора роста |
GB2467691A (en) | 2008-09-05 | 2010-08-11 | Aueon Inc | Methods for stratifying and annotating cancer drug treatment options |
JP2013507987A (ja) * | 2009-10-26 | 2013-03-07 | アボット・ラボラトリーズ | 非小細胞肺癌の予後を決定するための診断方法 |
US8609354B2 (en) * | 2010-03-04 | 2013-12-17 | Olli CARPEN | Method for selecting patients for treatment with an EGFR inhibitor |
AU2011222867B2 (en) | 2010-03-04 | 2014-03-06 | Annika Algars | Method for selecting patients for treatment with an EGFR inhibitor |
US20120045433A1 (en) * | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
WO2012040387A1 (en) | 2010-09-24 | 2012-03-29 | The Board Of Trustees Of The Leland Stanford Junior University | Direct capture, amplification and sequencing of target dna using immobilized primers |
DE102010060964A1 (de) * | 2010-12-02 | 2012-06-06 | Universitätsklinikum Hamburg-Eppendorf | Verfahren zur Prädikation der therapeutischen Wirksamkeit von EGFR-Inhibitoren |
US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
CN102153648B (zh) * | 2011-01-27 | 2012-07-04 | 中国人民解放军军事医学科学院生物工程研究所 | 一种抗egfr人源化抗体l4-h3及其编码基因与应用 |
MX2013011706A (es) | 2011-04-07 | 2014-04-25 | Amgen Inc | Proteinas novedosas de enlace a antigeno. |
EP2802671B1 (en) * | 2011-12-12 | 2018-07-18 | Cellay, Inc. | Methods and kits for room temperature in situ detection of a target nucleic acid in a biological sample |
CN105899539B (zh) | 2014-01-10 | 2021-11-09 | 博笛生物科技有限公司 | 用于免疫疗法的化合物和组合物 |
EP4001311A1 (en) | 2014-07-09 | 2022-05-25 | Birdie Biopharmaceuticals Inc. | Anti-pd-l1 combinations for treating tumors |
JP6782698B2 (ja) * | 2014-12-12 | 2020-11-11 | セルキュイティー インコーポレイテッド | がん患者を診断および処置するためのerbbシグナル伝達経路活性の測定方法 |
CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-cd20组合 |
CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-egfr组合 |
CN118515666A (zh) | 2017-04-27 | 2024-08-20 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
JP7080501B2 (ja) | 2017-06-23 | 2022-06-06 | バーディー バイオファーマシューティカルズ インコーポレイテッド | 医薬品組成物 |
EP3622522A1 (en) * | 2017-12-01 | 2020-03-18 | Illumina, Inc. | Methods and systems for determining somatic mutation clonality |
EP3591666A1 (en) * | 2018-07-04 | 2020-01-08 | Dassault Systèmes | Simulating evolution of a tumor |
CN112430646A (zh) * | 2020-12-11 | 2021-03-02 | 南京求臻基因科技有限公司 | 一种基于数字pcr平台的egfr基因扩增的检测方法 |
CN112646893A (zh) * | 2021-01-08 | 2021-04-13 | 北京泛生子基因科技有限公司 | 一种egfr基因拷贝数检测试剂盒及检测方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2407556C (en) * | 2000-05-19 | 2011-06-21 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
US20050164218A1 (en) * | 2003-05-30 | 2005-07-28 | David Agus | Gene expression markers for response to EGFR inhibitor drugs |
WO2006107854A2 (en) * | 2005-04-01 | 2006-10-12 | Amgen Inc. | Epidermal growth factor receptor gene copy number |
-
2006
- 2006-04-12 CN CNA2006800115475A patent/CN101155932A/zh active Pending
- 2006-04-12 MX MX2007012570A patent/MX2007012570A/es not_active Application Discontinuation
- 2006-04-12 RU RU2007141067/13A patent/RU2007141067A/ru not_active Application Discontinuation
- 2006-04-12 BR BRPI0610440-1A patent/BRPI0610440A2/pt not_active Application Discontinuation
- 2006-04-12 JP JP2008505803A patent/JP2008535508A/ja active Pending
- 2006-04-12 KR KR1020077026535A patent/KR20080003422A/ko not_active Application Discontinuation
- 2006-04-12 EP EP06724269A patent/EP1869208A1/en not_active Ceased
- 2006-04-12 WO PCT/EP2006/003358 patent/WO2006108627A1/en active Application Filing
- 2006-04-12 CA CA002604300A patent/CA2604300A1/en not_active Abandoned
- 2006-04-12 US US11/911,380 patent/US20090269344A1/en not_active Abandoned
- 2006-04-12 AU AU2006233675A patent/AU2006233675A1/en not_active Abandoned
-
2007
- 2007-11-13 ZA ZA200709780A patent/ZA200709780B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
KR20080003422A (ko) | 2008-01-07 |
CN101155932A (zh) | 2008-04-02 |
RU2007141067A (ru) | 2009-05-20 |
AU2006233675A1 (en) | 2006-10-19 |
JP2008535508A (ja) | 2008-09-04 |
WO2006108627A9 (en) | 2007-10-11 |
MX2007012570A (es) | 2007-11-16 |
EP1869208A1 (en) | 2007-12-26 |
CA2604300A1 (en) | 2006-10-19 |
WO2006108627A1 (en) | 2006-10-19 |
US20090269344A1 (en) | 2009-10-29 |
BRPI0610440A2 (pt) | 2010-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200709780B (en) | Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues | |
AU2006226897B2 (en) | Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors | |
IL238045A0 (en) | Tumor treatment with an antibody against vegf | |
CY2017013I2 (el) | ΑΝΤΙΣΩΜΑ ΕΝΑΝΤΙΟΝ PDGFR-α ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΟΓΚΩΝ | |
WO2006102272A8 (en) | Methods for treating tumors and cancerous tissues | |
WO2004113571A3 (en) | Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis | |
IL190537A0 (en) | Egfr dependent modulation of chemokine expression and influence on therapy and diagnosis of tumors and side effects thereof | |
EP1718145A4 (en) | CONJUGATES FOR CANCER THERAPY AND DIAGNOSIS | |
IL179891A0 (en) | Tumor specific antibody | |
IL190332A0 (en) | Human antibodies against il13 and therapeutic uses | |
HK1081448A1 (en) | Bispecific anti-erb-b antibodies and their use in tumor therapy | |
EP1720575A4 (en) | Therapeutic and diagnostic conjugates for use with multi-specific antibodies | |
IL188588A0 (en) | Anti-ctla -4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment | |
GB0519405D0 (en) | Cancer therapy prognosis and target | |
ZA200702973B (en) | Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer | |
AU2003224076A1 (en) | Antibody combination useful for tumor therapy | |
EP1742654A4 (en) | ANTI-LFL2 ANTIBODIES FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER | |
EP1976554A4 (en) | S-N-ACETYL SIALIC ACID ANTIGENS, ANTIBODIES THEREOF AND METHODS OF USE THEREOF IN ANTICANCER THERAPIES | |
WO2006027693A8 (en) | Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis | |
EP1756166A4 (en) | DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | |
WO2008003656A3 (en) | Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics | |
WO2010054377A3 (en) | Fully human antibodies against n-cadherin | |
AU2006251169A8 (en) | Tetrahydropyridothiophenes for use in the treatment of cancer | |
AU2006251167A8 (en) | Tetrahydropyridothiophenes for use in the treatment of cancer | |
EP1934331A4 (en) | PAX2 AS A TARGET FOR THE INDUCTION OF DEFB1-MEDIATED TUMORIMMUNITY AND CANCER THERAPY |